A nurse is caring for a client who has an acute respiratory failure (ARF). The nurse should monitor the client for which of the following manifestations of this condition? (Select all that apply.)

Choice A: Carvedilol is not a medication that interacts with contrast material and places the client at risk for acute kidney injury. Carvedilol is a beta-blocker that lowers blood pressure and heart rate by blocking the effects of adrenaline on the heart and blood vessels. Carvedilol does not affect kidney function or contrast excretion, but it can cause hypotension, bradycardia, or heart failure in some clients.

Choice B: Nitroglycerin is not a medication that interacts with contrast material and places the client at risk for acute kidney injury. Nitroglycerin is a vasodilator that relaxes the smooth muscles of the blood vessels and increases blood flow to the heart. Nitroglycerin does not affect kidney function or contrast excretion, but it can cause hypotension, headache, or flushing in some clients.

Choice C: Atorvastatin is not a medication that interacts with contrast material and places the client at risk for acute kidney injury. Atorvastatin is a statin that lowers cholesterol levels by inhibiting an enzyme that produces cholesterol in the liver. Atorvastatin does not affect kidney function or contrast excretion, but it can cause liver damage, muscle pain, or rhabdomyolysis in some clients.

Choice D: Metformin is a medication that interacts with contrast material and places the client at risk for acute kidney injury. Metformin is an oral antidiabetic drug that lowers blood glucose levels by decreasing hepatic glucose production and increasing insulin sensitivity. Metformin can accumulate in the kidneys and cause lactic acidosis, a life-threatening condition characterized by high levels of lactic acid in the blood. Contrast material can worsen kidney function and increase the risk of lactic acidosis in clients taking metformin. Therefore, metformin should be discontinued before and after the procedure as prescribed.

Choice A: Troponin I is a laboratory test that the nurse should anticipate the provider to prescribe. Troponin I is a protein that is released into the blood when the heart muscle is damaged. Troponin I levels are elevated in clients who have acute myocardial infarction (AMI), which is a heart atack caused by a blockage of blood flow to the heart. Chest pressure and shortness of breath are common signs and symptoms of AMI. Troponin I is a specific and sensitive marker of cardiac injury and can help diagnose AMI and guide treatment.

Choice B: Aspartate aminotransferase (AST) is not a laboratory test that the nurse should anticipate the provider to prescribe. AST is an enzyme that is found in various tissues, such as the liver, heart, skeletal muscle, and kidneys. AST levels are elevated in clients who have liver damage, hepatitis, cirrhosis, or alcohol abuse. AST levels can also be elevated in clients who have AMI, but they are not as specific or sensitive as troponin I. AST is not a reliable indicator of cardiac injury and can be influenced by other factors.

Choice C: B-type natriuretic peptide (BNP) is not a laboratory test that the nurse should anticipate the provider to prescribe. BNP is a hormone that is secreted by the heart when it is stretched or overloaded. BNP levels are elevated in clients who have heart failure, which is a condition in which the heart cannot pump enough blood to meet the

body's needs. Shortness of breath can be a sign of heart failure, but chest pressure is not. BNP is not a specific or sensitive marker of cardiac injury and can be influenced by other factors.

Choice D: Lipase is not a laboratory test that the nurse should anticipate the provider to prescribe. Lipase is an enzyme that is produced by the pancreas and helps digest fats. Lipase levels are elevated in clients who have pancreatitis, which is an inflammation of the pancreas. Pancreatitis can cause abdominal pain, nausea, vomiting, and fever. Chest pressure and shortness of breath are not signs of pancreatitis. Lipase is not a specific or sensitive marker of cardiac injury and has no relation to AMI.